Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026
Gilead and Kite will present 23 abstracts, including 7 orals, at the ASH annual meeting December 12-15, 2026, spanning the oncology pipeline and cell-therapy portfolio. The centerpiece is 18-month minimum follow-up from the pivotal Phase 2 iMMagine-1 study of anito-cel in relapsed/refractory multiple myeloma, plus new comparative analyses versus bispecifics and competing CAR-T therapies; anito-cel's FDA BLA is under review with a PDUFA date of December 23, 2026.
Key figures
- Drug Name
- anitocabtagene autoleucel (anito-cel)
- Phase Of Trial
- Phase 2
- Pdufa date
- December 23, 2026
- Zuma 12 followup
- 5-year
- Oral presentations
- 7
- Presentations total
- 23
- Imumagine 1 followup
- 18-month minimum
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.